AssertioASRT
ASRT
About: Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Employees: 30
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,726% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $117K
17.07% less ownership
Funds ownership: 48.24% [Q2] → 31.17% (-17.07%) [Q3]
19% less funds holding
Funds holding: 105 [Q2] → 85 (-20) [Q3]
38% less capital invested
Capital invested by funds: $56.9M [Q2] → $35.1M (-$21.8M) [Q3]
58% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 31
59% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 34
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
352%
upside
Avg. target
$4
352%
upside
High target
$4
352%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target | 352%upside $4 | Buy Reiterated | 16 Dec 2024 |
Financial journalist opinion
Based on 4 articles about ASRT published over the past 30 days
Neutral
GlobeNewsWire
4 days ago
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee.
Neutral
GlobeNewsWire
1 week ago
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced yesterday results of a clinical trial investigating the utility of Rolvedon ® (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC).
Positive
Zacks Investment Research
1 week ago
New Strong Buy Stocks for December 10th
CTV, GRAB, ASRT, POWL and LUV have been added to the Zacks Rank #1 (Strong Buy) List on December 10, 2024.
Positive
Zacks Investment Research
3 weeks ago
New Strong Buy Stocks for November 29th
MKTAY, ASRT, CHH, DRS and BRKL have been added to the Zacks Rank #1 (Strong Buy) List on November 29, 2024.
Neutral
Business Wire
1 month ago
Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today called upon the Senate Committee on Health, Education, Labor & Pensions (the “Committee”) to investigate the evident product-related fraud at.
Neutral
Seeking Alpha
1 month ago
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT ) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - CEO Ajay Patel - SVP & CFO Conference Call Participants Thomas Flaten - Lake Street Capital Markets Naz Rahman - Maxim Group Scott Henry - Alliance Global Partners Raghuram Selvaraju - H.C. Wainwright Operator Thank you for standing by.
Negative
Zacks Investment Research
1 month ago
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates
Assertio (ASRT) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.01 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Assertio Reports Third Quarter 2024 Financial Results
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today reported financial results for the third quarter ended September 30, 2024.
Neutral
Business Wire
1 month ago
Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity position into that of a short interest in the publicly traded securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today responded to the Company's attempt to deny, in its November 11, 2024, press release, the evident product-related fraud at Spectrum Pharmaceuticals, In.
Neutral
GlobeNewsWire
1 month ago
Assertio Provides Response to Letter from Short-seller
Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Taking Legal and Regulatory Action LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today issued the following letter from Chief Executive Officer Brendan O'Grady in response to public comments made November 8, 2024 by a short-seller: To the members of the investment community, As many of you have been aware, Mr.
Charts implemented using Lightweight Charts™